What did the FDA PCAC decide in July 2026?

On July 23 and 24 2026 the FDA Pharmacy Compounding Advisory Committee recommended six of seven reviewed peptides for potential inclusion on the 503A Bulks List. BPC-157, KPV and TB-500 were each recommended 8-6 with one abstention. MOTS-c was recommended 7-5 with two abstentions. Epitalon was recommended 7-5 with one abstention. Semax was recommended 8-5. Emideltide, also known as DSIP, was not recommended in a 6-7 vote with one abstention. This information is for research and educational purposes only and is not medical advice.

Which peptides were reviewed at the July 2026 PCAC meeting?

The seven peptides reviewed at the July 23-24 2026 PCAC meeting were BPC-157, TB-500, KPV, MOTS-c, DSIP (Emideltide), Semax, and Epitalon. These were previously placed in Category 2 in 2023 due to safety concerns and limited human exposure data. This information is for research and educational purposes only and is not medical advice.

What does the PCAC recommendation mean for compounding access?

A favorable PCAC recommendation advises the FDA Commissioner to consider adding a substance to the 503A Bulks List, which would create a pathway for state-licensed compounding pharmacies to prepare patient-specific medications under a valid prescription. The recommendations are non-binding and require further FDA action and a rulemaking process before any change takes effect. Each recommendation applies to the specific use the committee reviewed. This information is for research and educational purposes only and is not medical advice.

Are the peptides FDA approved after the July 2026 PCAC meeting?

No. A positive PCAC recommendation means the committee advised the FDA Commissioner to consider adding the substance to the 503A Bulks List for licensed compounding use with a valid prescription. It does not constitute FDA drug approval. The FDA Commissioner makes the final determination and implementation takes additional time. This information is for research and educational purposes only and is not medical advice.

What happens after the July 2026 PCAC meeting?

The recommendations move to the FDA Commissioner, who is not required to follow them. Formal inclusion on the 503A Bulks List would require additional agency action and a rulemaking process that typically takes a year or more. A second PCAC meeting is scheduled before February 2027 to review additional peptides including Melanotan II. This information is for research and educational purposes only and is not medical advice.

FDA PCAC July 2026 Results -- What It Means

Summary

The FDA's Pharmacy Compounding Advisory Committee reviewed seven peptides on July 23 and 24, 2026, and recommended six of them for potential inclusion on the Section 503A Bulk Drug Substances List.

BPC-157, KPV, TB-500, MOTS-c, Semax and Epitalon all received favorable votes. Emideltide, also known as DSIP, did not.

The most significant detail was not in most coverage. FDA's own scientific briefing documents recommended against adding any of the seven. The committee reviewed those documents, heard from clinicians, pharmacists and patients, and voted the other way six consecutive times.

An advisory panel departing from its agency's written position is uncommon. Doing it six times across two days is close to unprecedented in compounding policy.

The field moved closer to regulated access this week than it has at any point since 2023.

What Was Decided

The committee considered each substance in both its free base and acetate salt forms. The votes broke identically across both forms.

Day one, July 23, 2026

BPC-157, reviewed for ulcerative colitis. Recommended, 8-6 with one abstention.
KPV, reviewed for wound healing and inflammatory conditions including psoriasis and eczema. Recommended, 8-6 with one abstention.
TB-500, reviewed for wound healing. Recommended, 8-6 with one abstention.
MOTS-c, reviewed for obesity and osteoporosis. Recommended, 7-5 with two abstentions.

Day two, July 24, 2026

Epitalon, reviewed for insomnia. Recommended, 7-5 with one abstention.
Semax, reviewed for cerebral ischemia, migraine and trigeminal neuralgia. Recommended, 8-5.
Emideltide, also called DSIP, reviewed for chronic insomnia, narcolepsy and opioid withdrawal. Not recommended, 6-7 with one abstention.

Each recommendation is specific to the use that was reviewed. A favorable vote on BPC-157 is a favorable vote on BPC-157 for ulcerative colitis.

Vote detail and committee deliberation are documented in the FDA Pharmacy Compounding Advisory Committee meeting materials and in reporting from RAPS Regulatory Focus.

The Larger Peptide Context

The compounding decision is one half of what is happening in peptide medicine, and it is the smaller half.

Roughly 130 peptide-based drugs already carry FDA approval, a line running from insulin in the 1920s through the metabolic therapies that have reshaped medicine over the past five years.

Semaglutide was approved for cardiovascular risk reduction in 2024 and for reducing kidney disease progression risk in 2025. Tirzepatide was approved for obstructive sleep apnea in 2024. Each approval moved a peptide out of a single metabolic indication and into cardiology, nephrology and sleep medicine.

The next generation is larger still. Eli Lilly's retatrutide is a triple hormone receptor agonist peptide targeting the GIP, GLP-1 and glucagon receptors. It anchors TRIUMPH, a Phase 3 program of eight pivotal trials enrolling more than 5,800 participants alongside a separate large cardiovascular outcomes trial.

In May 2026 the company reported topline TRIUMPH-1 results: participants on the 12 mg dose lost an average of 70.3 pounds, 28.3 percent of body weight, over 80 weeks, with more than 45 percent losing at least 30 percent of body weight.

A study extension reported an average of 30.3 percent at 104 weeks in participants with baseline BMI of 35 or higher. Seven further Phase 3 readouts are expected during 2026.

Retatrutide is investigational and not approved in any market. The point is structural rather than product specific. The largest pharmaceutical company in the world has built its next flagship program on a peptide. Peptide science is not a category seeking legitimacy. It is where mainstream medicine is already investing, and the compounding framework is catching up to it.

That is the context in which this week's vote should be read.

Peptide by Peptide Breakdown

BPC-157

Recommended, 8-6 with one abstention, reviewed for ulcerative colitis. BPC-157 is the most widely discussed research peptide in the United States, and its favorable vote is the headline outcome of the meeting for most of the field.

Read the full research profile for BPC-157.

TB-500

Recommended, 8-6 with one abstention, reviewed for wound healing. A fragment of thymosin beta-4. Its inclusion in the successful group strengthens the case for standardized sourcing and pharmacy-grade preparation.

Read the full research profile for TB-500.

KPV

Recommended, 8-6 with one abstention, reviewed for wound healing and inflammatory conditions including psoriasis and eczema. A tripeptide fragment of alpha-MSH. Its favorable vote extends the meeting into dermatology and inflammation research.

Read the full research profile for KPV.

MOTS-c

Recommended, 7-5 with two abstentions, reviewed for obesity and osteoporosis. A mitochondrial-derived peptide. Its favorable vote brings mitochondrial signaling research into a formal federal process for the first time.

Read the full research profile for MOTS-c.

DSIP (Emideltide)

Not recommended, 6-7 with one abstention, reviewed for chronic insomnia, narcolepsy and opioid withdrawal. Committee members cited insufficient characterization data and evidence limited to intravenous administration rather than the nominated subcutaneous route. Emideltide was the only substance of the seven to receive an unfavorable vote.

Read the full research profile for DSIP.

Semax

Recommended, 8-5, reviewed for cerebral ischemia, migraine and trigeminal neuralgia. A synthetic ACTH fragment with a long history of clinical use outside the United States. Its recommendation extends the meeting into neurology.

Read the full research profile for Semax.

Epitalon

Recommended, 7-5 with one abstention, reviewed for insomnia. A tetrapeptide associated with telomere and aging research. Its favorable vote keeps that line of investigation inside the regulatory conversation.

Read the full research profile for Epitalon.

What Happens Next

PCAC recommendations are advisory and non-binding. The committee has issued its recommendations, and they now sit with the FDA Commissioner, who reviews them and makes the final determination. The Commissioner may accept, modify, or reject the committee's advice, so the July recommendations are a step in the process rather than the final word.

If the FDA decides to add one or more substances to the 503A Bulks List, implementation typically takes additional time after the recommendation, often a matter of months, as the agency completes its formal rulemaking and updates the list. Until that step is complete, the practical status of a substance may not change immediately.

A second PCAC meeting is scheduled before February 2027 to review additional peptides, including Melanotan II. In the coming months, researchers can watch the FDA advisory committee calendar and the Federal Register for published materials, meeting minutes, and any updates to the 503A Bulks List, which will indicate how the recommendations are being acted on.

What This Means for Researchers

Across the six favorable votes, the committee endorsed peptides spanning inflammation, wound healing, gastrointestinal research, metabolic health, neurology, and sleep and aging biology. That breadth is the practical argument for the field. Peptides are signaling molecules, and signaling reaches into every system.

Nothing about access changes today. What changed is position. Six substances now sit further along a formal federal pathway than at any prior point, with an advisory panel on record supporting them.

The useful response to that is preparation rather than anticipation. Understanding your own baseline biology is what converts a future access decision into an informed one.

Regardless of the regulatory outcome, Pepvela's position remains the same: understand your biology first. Know your baseline biomarkers. Understand the research. Work with a licensed healthcare provider. The regulatory status of any substance does not change the importance of informed, data-driven decision making.

All Seven Peptides Under Review

The seven peptides reviewed at the July 2026 PCAC meeting each have a full research profile in the Pepvela library.

BPC-157: Studied in preclinical research for tissue repair, including tendon, ligament, and gut mucosal healing.
TB-500: A synthetic fragment related to Thymosin Beta-4, studied for actin regulation and tissue remodeling.
KPV: A tripeptide fragment of alpha-MSH examined for anti-inflammatory activity in research models.
MOTS-c: A mitochondrial-derived peptide studied for metabolic regulation and the response to exercise.
DSIP (Emideltide): A delta sleep-inducing peptide studied for sleep architecture and HPA-axis context.
Semax: A synthetic peptide related to an ACTH fragment, investigated for cognition and neuroprotection.
Epitalon: A synthetic tetrapeptide studied in the context of telomere biology and longevity research.

References

FDA Advisory Committee Calendar -- July 23-24 2026 PCAC Meeting -- fda.gov
FDA Federal Register Notice -- April 15 2026 -- Pharmacy Compounding Advisory Committee Meeting
RAPS Regulatory Focus -- "FDA advisory committee backs two more peptides, rejects one for compounding list" -- July 24, 2026 -- raps.org
Pepvela Research -- "FDA Peptide Advisory Panel July 2026: What Researchers Need to Know" -- pepvela.com/research/fda-peptide-review-july-2026

FDA PCAC July 2026 Results: What the Decision Means for Peptide Research